References
- Miller KD, Fidler‐Benaoudia M, Keegan TH, et al. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020;70(6):443–459.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020Jan;70(1):7–30. PubMed PMID: 31912902. https://doi.org/10.3322/caac.21590
- Pelosi E, Castelli G, Testa U. Pancreatic cancer: molecular characterization, clonal evolution and cancer stem cells. Biomedicines. 2017 Nov 18;5(4):65. DOI:https://doi.org/10.3390/biomedicines5040065. PubMed PMID: 29156578; PubMed Central PMCID: PMCPMC5744089.
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018Nov;686:394–424. https://doi.org/10.3322/caac.21492 PubMed PMID: 30207593
- Collaborators GBDPC. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–947. doi: https://doi.org/10.1016/S2468-1253(19)30347-4. PubMed PMID: 31648972; eng.
- Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913–2921. PubMed PMID: 24840647. DOI:https://doi.org/10.1158/0008-5472.CAN-14-0155.
- Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378(9791):607–620.
- Lei F, Xi X, Batra SK, et al. Combination therapies and drug delivery platforms in combating pancreatic cancer. J Pharmacol Exp Ther. 2019Sep;370(3):682–694. https://doi.org/10.1124/jpet.118.255786 PubMed PMID: 30796131; PubMed Central PMCID: PMCPMC6806650
- Gebregiworgis T, Bhinderwala F, Purohit V, et al. Insights into gemcitabine resistance and the potential for therapeutic monitoring. Metabolomics. 2018 Nov 27;14(12):156. PubMed PMID: 30830412; PubMed Central PMCID: PMCPMC6620022. DOI:https://doi.org/10.1007/s11306-018-1452-7.
- Wei L, Wen JY, Chen J, et al. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer. World J Gastroenterol. 2019 Oct 7;25(37):5590–5603. PubMed PMID: 31602160; PubMed Central PMCID: PMCPMC6785518. DOI:https://doi.org/10.3748/wjg.v25.i37.5590.
- Binenbaum Y, Na’ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat. 2015Nov; 23: 55–68.https://doi.org/10.1016/j.drup.2015.10.002 PubMed PMID: 26690340
- Chin V, Nagrial A, Sjoquist K, et al. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev. 2018 Mar 20;3: CD011044. doi: https://doi.org/10.1002/14651858.CD011044.pub2. PubMed PMID: 29557103; PubMed Central PMCID: PMCPMC6494171
- Lee HS, Park SW. Systemic chemotherapy in advanced pancreatic cancer. Gut Liver. 2016 May 23;10(3):340–347. DOI:https://doi.org/10.5009/gnl15465. PubMed PMID: 27114434; PubMed Central PMCID: PMCPMC4849685.
- Hu J, Zhao G, Wang HX, et al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol. 2011 Mar 26;4:11. DOI:https://doi.org/10.1186/1756-8722-4-11. PubMed PMID: 21439076; PubMed Central PMCID: PMCPMC3079694.
- Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019 Aug 1;111(8):782–794. PubMed PMID: 31086963; PubMed Central PMCID: PMCPMC6695305. DOI:https://doi.org/10.1093/jnci/djz073.
- Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–810.
- Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018 Dec 20;379(25):2395–2406. PubMed PMID: 30575490. DOI:https://doi.org/10.1056/NEJMoa1809775.
- Giordano G, Pancione M, Olivieri N, et al. Nano albumin bound-paclitaxel in pancreatic cancer: current evidences and future directions. World J Gastroenterol. 2017;23(32):5875–5886. PubMed PMID: 28932079; eng. DOI:https://doi.org/10.3748/wjg.v23.i32.5875
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. PubMed PMID: 24131140; eng. DOI:https://doi.org/10.1056/NEJMoa1304369
- Hall BR, Cannon A, Atri P, et al. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Oncotarget. 2018;9(27):19396–19405. PubMed PMID: 29721211; eng. DOI:https://doi.org/10.18632/oncotarget.25036
- von Ahrens D, Bhagat TD, Nagrath D, et al. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol. 2017 Mar 28;10(1):76. PubMed PMID: 28351381; PubMed Central PMCID: PMCPMC5371211. DOI:https://doi.org/10.1186/s13045-017-0448-5.
- Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016 Aug 23;16(9):582–598. DOI:https://doi.org/10.1038/nrc.2016.73. PubMed PMID: 27550820.
- Ohlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017 Mar 6;214(3):579–596. PubMed PMID: 28232471; PubMed Central PMCID: PMCPMC5339682. DOI:https://doi.org/10.1084/jem.20162024.
- Hessmann E, Buchholz SM, Demir IE, et al. Microenvironmental determinants of pancreatic cancer. Physiol Rev. 2020 Oct 1;100(4):1707–1751. PubMed PMID: 32297835. DOI:https://doi.org/10.1152/physrev.00042.2019.
- Choi JI, Jang SI, Hong J, et al. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells. Cancer Lett. 2021 Feb 1;498:42–53. DOI:https://doi.org/10.1016/j.canlet.2020.10.012. PubMed PMID: 33188841.
- Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020Aug;17(8):487–505. PubMed PMID: 32393771; PubMed Central PMCID: PMCPMC8284850. https://doi.org/10.1038/s41575-020-0300-1
- Endo S, Nakata K, Ohuchida K, et al. Autophagy is required for activation of pancreatic stellate cells, associated with pancreatic cancer progression and promotes growth of pancreatic tumors in mice. Gastroenterology. 2017May;1526:1492–1506 e24. https://doi.org/10.1053/j.gastro.2017.01.010 PubMed PMID: 28126348
- Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec 19-26;420(6917):860–867. DOI:https://doi.org/10.1038/nature01322. PubMed PMID: 12490959; PubMed Central PMCID: PMCPMC2803035.
- Calon A, Tauriello DV, Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol. 2014Apr; 25: 15–22.https://doi.org/10.1016/j.semcancer.2013.12.008 PubMed PMID: 24412104
- Biffi G, Oni TE, Spielman B, et al. IL1-induced jak/stat signaling is antagonized by tgfbeta to shape caf heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019Feb;92:282–301. https://doi.org/10.1158/2159-8290.CD-18-0710 PubMed PMID: 30366930; PubMed Central PMCID: PMCPMC6368881
- Norton J, Foster D, Chinta M, et al. Pancreatic cancer associated fibroblasts (caf): under-explored target for pancreatic cancer treatment. Cancers (Basel). 2020 May 25;12(5):1347. PubMed PMID: 32466266; PubMed Central PMCID: PMCPMC7281461. DOI:https://doi.org/10.3390/cancers12051347.
- Öhlund D, Franklin O, Lundberg E, et al. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer. 2013;13:154. PubMed PMID: 23530721; eng. DOI:https://doi.org/10.1186/1471-2407-13-154
- Wang WQ, Liu L, Xu JZ, et al. Reflections on depletion of tumor stroma in pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2019Apr;18712:267–272. https://doi.org/10.1016/j.bbcan.2019.01.007 PubMed PMID: 30738097
- Neesse A, Bauer CA, Ohlund D, et al. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut. 2019Jan;681:159–171. https://doi.org/10.1136/gutjnl-2018-316451 PubMed PMID: 30177543
- Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–120.
- Choi KY, Han HS, Lee ES, et al. Hyaluronic acid-based activatable nanomaterials for stimuli-responsive imaging and therapeutics: beyond cd44-mediated drug delivery. Adv Mater. 2019Aug;3134:e1803549. https://doi.org/10.1002/adma.201803549 PubMed PMID: 30773699
- Toole BP, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol. 2008;18(4):244–250. PubMed PMID: 18534864; eng. DOI:https://doi.org/10.1016/j.semcancer.2008.03.009
- Abatangelo G, Vindigni V, Avruscio G, et al. Hyaluronic acid: redefining its role. Cells. 2020 Jul 21;9(7):1743. PubMed PMID: 32708202; PubMed Central PMCID: PMCPMC7409253. DOI:https://doi.org/10.3390/cells9071743.
- Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23(7–8):605–618. PubMed PMID: 26453158. DOI:https://doi.org/10.3109/1061186X.2015.1052072
- Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007Jun;26(2):225–239. PubMed PMID: 17440684. https://doi.org/10.1007/s10555-007-9055-1
- Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000;48(4):919–922.
- Duffy JP, Eibl G, Reber HA, et al. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer. 2003;2:12. PubMed PMID: 12605718; eng. DOI:https://doi.org/10.1186/1476-4598-2-12
- Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004Jul;14(3):198–206. PubMed PMID: 15254862. https://doi.org/10.1016/j.semradonc.2004.04.008
- Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol. 2016;10(3):301–316. PubMed PMID: 26560854. DOI:https://doi.org/10.1586/17474124.2016.1117386
- Shah VM, Sheppard BC, Sears RC, et al. Hypoxia: friend or foe for drug delivery in pancreatic cancer. Cancer Lett. 2020 Nov 1;492:63–70. DOI:https://doi.org/10.1016/j.canlet.2020.07.041. PubMed PMID: 32822815; PubMed Central PMCID: PMCPMC7879337.
- Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012Apr;33(4):207–214. PubMed PMID: 22398146; PubMed Central PMCID: PMCPMC3437546. https://doi.org/10.1016/j.tips.2012.01.005
- Yamasaki A, Yanai K, Onishi H. Hypoxia and pancreatic ductal adenocarcinoma. Cancer Lett. 2020 Aug 1;484:9–15. DOI:https://doi.org/10.1016/j.canlet.2020.04.018. PubMed PMID: 32380129.
- Tan Z, Xu J, Zhang B, et al. Hypoxia: a barricade to conquer the pancreatic cancer. Cell Mol Life Sci. 2020;77(16):3077–3083.
- Tao J, Yang G, Zhou W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021 Jan 13;14(1):14. PubMed PMID: 33436044; PubMed Central PMCID: PMCPMC7805044. DOI:https://doi.org/10.1186/s13045-020-01030-w.
- Daniel SK, Sullivan KM, Labadie KP, et al. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. Clin Transl Med. 2019 Apr 1;8(1):10. PubMed PMID: 30931508; PubMed Central PMCID: PMCPMC6441665. DOI:https://doi.org/10.1186/s40169-019-0226-9.
- Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci. 2019 Feb 5;20(3):676. DOI:https://doi.org/10.3390/ijms20030676. PubMed PMID: 30764482; PubMed Central PMCID: PMCPMC6387440.
- Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to t cell activity: a case for synergistic therapies. Cancer Cell. 2017 Mar 13;31(3):311–325. DOI:https://doi.org/10.1016/j.ccell.2017.02.008. PubMed PMID: 28292435; PubMed Central PMCID: PMCPMC5423788.
- Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020May;5817806:100–105. https://doi.org/10.1038/s41586-020-2229-5 PubMed PMID: 32376951; PubMed Central PMCID: PMCPMC7296553
- Yamamoto K, Venida A, Perera RM, et al. Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer. Autophagy. 2020Aug;168:1524–1525. https://doi.org/10.1080/15548627.2020.1769973 PubMed PMID: 32459143; PubMed Central PMCID: PMCPMC7469632
- Leinwand J, Miller G. Regulation and modulation of antitumor immunity in pancreatic cancer. Nat Immunol. 2020Oct;21(10):1152–1159. PubMed PMID: 32807942. https://doi.org/10.1038/s41590-020-0761-y
- Worbs T, Hammerschmidt SI, Forster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017Jan;17(1):30–48. PubMed PMID: 27890914. https://doi.org/10.1038/nri.2016.116
- Patente TA, Pinho MP, Oliveira AA, et al. Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. Front Immunol. 2018;9:3176. PubMed PMID: 30719026; PubMed Central PMCID: PMCPMC6348254. DOI:https://doi.org/10.3389/fimmu.2018.03176
- Nie Y, Yang D, Oppenheim JJ. Alarmins and antitumor immunity. Clin Ther. 2016May;38(5):1042–1053. PubMed PMID: 27101817; PubMed Central PMCID: PMCPMC6314656. https://doi.org/10.1016/j.clinthera.2016.03.021
- Hegde S, Krisnawan VE, Herzog BH, et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell. 2020 Mar 16;37(3):289–307 e9. PubMed PMID: 32183949; PubMed Central PMCID: PMCPMC7181337. DOI:https://doi.org/10.1016/j.ccell.2020.02.008.
- Anderson NR, Minutolo NG, Gill S, et al. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2021 Mar 1;81(5):1201–1208. PubMed PMID: 33203697. DOI:https://doi.org/10.1158/0008-5472.CAN-20-2990.
- Muraoka D, Seo N, Hayashi T, et al. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J Clin Invest. 2019 Mar 1;129(3):1278–1294. PubMed PMID: 30628894; PubMed Central PMCID: PMCPMC6391090. DOI:https://doi.org/10.1172/JCI97642.
- Broz ML, Binnewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014 Nov 10;26(5):638–652. PubMed PMID: 25446897; PubMed Central PMCID: PMCPMC4254577. DOI:https://doi.org/10.1016/j.ccell.2014.09.007.
- Mehla K, Singh PK. Metabolic regulation of macrophage polarization in cancer. Trends Cancer. 2019Dec;5(12):822–834. PubMed PMID: 31813459; PubMed Central PMCID: PMCPMC7187927. https://doi.org/10.1016/j.trecan.2019.10.007
- Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005Oct;23(4):344–346. PubMed PMID: 16226499. https://doi.org/10.1016/j.immuni.2005.10.001
- von Itzstein Ms, Burke MC, Brekken RA, et al. Targeting TAM to tame pancreatic cancer. Target Oncol. 2020Oct;155:579–588. https://doi.org/10.1007/s11523-020-00751-9 PubMed PMID: 32996059; PubMed Central PMCID: PMCPMC7583676
- Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;2002May01;196(3):254–265. DOI:https://doi.org/10.1002/path.1027
- Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009Mar;9(3):162–174. PubMed PMID: 19197294; PubMed Central PMCID: PMCPMC2828349. https://doi.org/10.1038/nri2506
- Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010Nov;40(11):2969–2975. PubMed PMID: 21061430; PubMed Central PMCID: PMCPMC3277452. https://doi.org/10.1002/eji.201040895
- Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019Jan;120(1):16–25. https://doi.org/10.1002/eji.201040895 PubMed PMID: 30413826; PubMed Central PMCID: PMCPMC6325125
- Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006Feb;16(1):53–65. PubMed PMID: 16168663. https://doi.org/10.1016/j.semcancer.2005.07.005
- Ziegler SF. Division of labour by CD4(+) T helper cells. Nat Rev Immunol. 2016Jul;16(7):403. PubMed PMID: 27140479. https://doi.org/10.1038/nri.2016.53
- Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011 Aug 26;35(2):161–168. DOI:https://doi.org/10.1016/j.immuni.2011.07.010. PubMed PMID: 21867926; PubMed Central PMCID: PMCPMC3303224.
- Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002 Sep 1;169(5):2756–2761. PubMed PMID: 12193750. DOI:https://doi.org/10.4049/jimmunol.169.5.2756.
- Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019May;156(7):2056–2072. PubMed PMID: 30660727; PubMed Central PMCID: PMCPMC6486864. https://doi.org/10.1053/j.gastro.2018.12.038
- Zhang Y, Lazarus J, Steele NG, et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 2020Mar;10(3):422–439. https://doi.org/10.1158/2159-8290.CD-19-0958 PubMed PMID: 31911451; PubMed Central PMCID: PMCPMC7224338
- Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018 Sep 19;16(1):71. PubMed PMID: 30231877; PubMed Central PMCID: PMCPMC6145203. DOI:https://doi.org/10.1186/s12951-018-0392-8.
- Liu J, Huang Y, Kumar A, et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2014Jul-Aug;324:693–710. https://doi.org/10.1016/j.biotechadv.2013.11.009 PubMed PMID: 24309541
- Raza A, Hayat U, Rasheed T, et al. Redox-responsive nano-carriers as tumor-targeted drug delivery systems. Eur J Med Chem. 2018 Sep 5;157:705–715. DOI:https://doi.org/10.1016/j.ejmech.2018.08.034. PubMed PMID: 30138802.
- Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014Nov;13(11):813–827. PubMed PMID: 25287120; PubMed Central PMCID: PMCPMC4489143. https://doi.org/10.1038/nrd4333
- Sato K, Yoshida K, Takahashi S, et al. pH- and sugar-sensitive layer-by-layer films and microcapsules for drug delivery. Adv Drug Deliv Rev. 2011 Aug 14;63(9):809–821. PubMed PMID: 21510988. DOI:https://doi.org/10.1016/j.addr.2011.03.015.
- Chang M, Zhang F, Wei T, et al. Smart linkers in polymer-drug conjugates for tumor-targeted delivery. J Drug Target. 2016;24(6):475–491. PubMed PMID: 26560242. DOI:https://doi.org/10.3109/1061186X.2015.1108324
- Wang Y, Pisapati AV, Zhang XF, et al. Recent developments in nanomaterial-based shear-sensitive drug delivery systems. Adv Healthc Mater. 2021Jul;10(13):e2002196. https://doi.org/10.1002/adhm.202002196 PubMed PMID: 34076369; PubMed Central PMCID: PMCPMC8273148
- Perez VM, Kearney JF, Yeh JJ. The PDAC extracellular matrix: a review of the ecm protein composition, tumor cell interaction, and therapeutic strategies. Front Oncol. 2021;11:751311. DOI:https://doi.org/10.3389/fonc.2021.751311. PubMed PMID: 34692532; PubMed Central PMCID: PMCPMC8526858.
- Zhao J, Zhang B, Shen S, et al. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery. J Colloid Interface Sci. 2015 ;450:396–403. 2015/jul/15/. DOI:https://doi.org/10.1016/j.jcis.2015.03.019.
- Okur AC, Erkoc P, Kizilel S. Targeting cancer cells via tumor-homing peptide CREKA functional PEG nanoparticles. Colloids Surf B Biointerfaces. 2016 2016/December/01/;147:191–200. DOI:https://doi.org/10.1016/j.colsurfb.2016.08.005.
- Kondo E, Iioka H, Saito K. Tumor-homing peptide and its utility for advanced cancer medicine. Cancer Sci. 2021;112(6):2118–2125. PubMed PMID: 33793015; eng. DOI:https://doi.org/10.1111/cas.14909
- Chan A, Prassas I, Dimitromanolakis A, et al. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res. 2014;20(22):5787–5795. PubMed PMID: 25239611; eng. DOI:https://doi.org/10.1158/1078-0432.CCR-14-0289
- Liang C, Qin Y, Zhang B, et al. Oncogenic KRAS targets muc16/ca125 in pancreatic ductal adenocarcinoma. Mol Cancer Res. 2017;15(2):201.
- Okada K-I, Kawai M, Tani M, et al. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma . J Hepatobiliary Pancreat Sci. 2014;2014 Sep 01;21(9:648–653. DOI:https://doi.org/10.1002/jhbp.109
- Gu L, Yan W, Liu S, et al. Trypsin enhances aptamer screening: a novel method for targeting proteins. Anal Biochem. 2018 ;561-562:89–95. 2018/December/15/. DOI:https://doi.org/10.1016/j.ab.2018.09.004.
- Zhou W, Zhou Y, Chen X, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021 Jan;268:120546. PubMed PMID: 33253966 https://doi.org/10.1016/j.biomaterials.2020.120546
- Zhou W, Chen X, Zhou Y, et al. Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer. Biomaterials. 2022 ;280:121306. 2022/Jan/01. DOI:https://doi.org/10.1016/j.biomaterials.2021.121306.
- Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156(4):1363–1380. PubMed PMID: 10751361; eng. DOI:https://doi.org/10.1016/S0002-9440(10)65006-7
- Padera TP, Stoll BR, Tooredman JB, et al. Cancer cells compress intratumour vessels. Nature. 2004 ;427(6976):695.
- Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010Nov;7(11):653–664. PubMed PMID: 20838415; PubMed Central PMCID: PMCPMC3065247. https://doi.org/10.1038/nrclinonc.2010.139
- Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 2007 Mar 15;67(6):2729–2735. DOI:https://doi.org/10.1158/0008-5472.CAN-06-4102. PubMed PMID: 17363594; PubMed Central PMCID: PMCPMC3022341.
- Wang J, Mao W, Lock LL, et al. The role of micelle size in tumor accumulation, penetration, and treatment. ACS Nano. 2015 ;9(7):7195–7206.
- Huang K, Ma H, Liu J, et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano. 2012 ;6(5):4483–4493.
- Cun X, Chen J, Li M, et al. Tumor-associated fibroblast-targeted regulation and deep tumor delivery of chemotherapeutic drugs with a multifunctional size-switchable nanoparticle. ACS Appl Mater Interfaces. 2019 Oct 30;11(43):39545–39559. PubMed PMID: 31617997. DOI:https://doi.org/10.1021/acsami.9b13957.
- Huo D, Liu S, Zhang C, et al. Hypoxia-targeting, tumor microenvironment responsive nanocluster bomb for radical-enhanced radiotherapy. ACS Nano. 2017 Oct 24;11(10):10159–10174. PubMed PMID: 28992409. DOI:https://doi.org/10.1021/acsnano.7b04737.
- Yu Q, Tang X, Zhao W, et al. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles. Acta Biomater. 2021 Oct 1;133:244–256. DOI:https://doi.org/10.1016/j.actbio.2021.05.002. PubMed PMID: 34000465.
- Zhao X, Yang X, Wang X, et al. Penetration cascade of size switchable nanosystem in desmoplastic stroma for improved pancreatic cancer therapy. ACS Nano. 2021 Sep 28;15(9):14149–14161. PubMed PMID: 34478262. DOI:https://doi.org/10.1021/acsnano.0c08860.
- Tong QS, Miao WM, Huang H, et al. A tumor-penetrating nanomedicine improves the chemoimmunotherapy of pancreatic cancer. Small. 2021Jul;1729:e2101208. https://doi.org/10.1002/smll.202101208 PubMed PMID: 34145747
- Li HJ, Du JZ, Liu J, et al. Smart superstructures with ultrahigh ph-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration. ACS Nano. 2016 Jul 26;10(7):6753–6761. PubMed PMID: 27244096. DOI:https://doi.org/10.1021/acsnano.6b02326.
- Zhang X, Detering L, Sultan D, et al. CC chemokine receptor 2-targeting copper nanoparticles for positron emission tomography-guided delivery of gemcitabine for pancreatic ductal adenocarcinoma. ACS nano. 2021;15(1):1186–1198. PubMed PMID: 33406361; eng. DOI:https://doi.org/10.1021/acsnano.0c08185
- Zhao F, Zhao Y, Liu Y, et al. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small. 2011 May 23;7(10):1322–1337. PubMed PMID: 21520409. DOI:https://doi.org/10.1002/smll.201100001.
- Forest V, Pourchez J. Preferential binding of positive nanoparticles on cell membranes is due to electrostatic interactions: a too simplistic explanation that does not take into account the nanoparticle protein corona. Mater Sci Eng C Mater Biol Appl. 2017 Jan 1;70(Pt 1):889–896. DOI:https://doi.org/10.1016/j.msec.2016.09.016. PubMed PMID: 27770966.
- Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv. 2011Mar;8(3):343–357. PubMed PMID: 21291354. https://doi.org/10.1517/17425247.2011.554818
- Sun Q, Zhou Z, Qiu N, et al. Rational design of cancer nanomedicine: nanoproperty integration and synchronization. Adv Mater. 2017Apr;2914:1606628. https://doi.org/10.1002/adma.201606628 PubMed PMID: 28234430
- Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013Nov;12(11):991–1003. PubMed PMID: 24150417. https://doi.org/10.1038/nmat3776
- Bahrami A, Hassanian SM, Khazaei M, et al. The therapeutic potential of targeting tumor microenvironment in breast cancer: rational strategies and recent progress. J Cell Biochem. 2018Jan;1191:111–122. https://doi.org/10.1002/jcb.26183 PubMed PMID: 28574616
- Huber V, Camisaschi C, Berzi A, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol. 2017 Apr;43:74–89. PubMed PMID: 28267587 https://doi.org/10.1016/j.semcancer.2017.03.001
- Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020 Feb 10;82:103–126. DOI:https://doi.org/10.1146/annurev-physiol-021119-034627. PubMed PMID: 31730395.
- Zhang M, Chen X, Li C, et al. Charge-reversal nanocarriers: an emerging paradigm for smart cancer nanomedicine. J Control Release. 2020 Mar 10;319:46–62. DOI:https://doi.org/10.1016/j.jconrel.2019.12.024. PubMed PMID: 31846619.
- Fang L, Lin H, Wu Z, et al. In vitro/vivo evaluation of novel mitochondrial targeting charge-reversal polysaccharide-based antitumor nanoparticle. Carbohydr Polym. 2020 Apr 15;234:115930. DOI:https://doi.org/10.1016/j.carbpol.2020.115930. PubMed PMID: 32070547.
- Feng Y, Xie X, Zhang H, et al. Multistage-responsive nanovehicle to improve tumor penetration for dual-modality imaging-guided photodynamic-immunotherapy. Biomaterials. 2021 Aug;275:120990. PubMed PMID: 34186239 https://doi.org/10.1016/j.biomaterials.2021.120990
- Zhou Q, Shao S, Wang J, et al. Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy. Nat Nanotechnol. 2019Aug;148:799–809. https://doi.org/10.1038/s41565-019-0485-z PubMed PMID: 31263194
- Wang G, Zhou Z, Zhao Z, et al. Enzyme-triggered transcytosis of dendrimer-drug conjugate for deep penetration into pancreatic tumors. ACS Nano. 2020 Apr 28;14(4):4890–4904. PubMed PMID: 32286784. DOI:https://doi.org/10.1021/acsnano.0c00974.
- He X, Chen X, Liu L, et al. Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic cancer therapy. Adv Sci (Weinh). 2018May;55:1701070. https://doi.org/10.1002/advs.201701070 PubMed PMID: 29876225; PubMed Central PMCID: PMCPMC5979633
- Wang Q, Li J, An S, et al. Magnetic resonance-guided regional gene delivery strategy using a tumor stroma-permeable nanocarrier for pancreatic cancer. Int J Nanomedicine. 2015;10:4479–4490. PubMed PMID: 26203245; eng. DOI:https://doi.org/10.2147/IJN.S84930
- Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, et al. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020 Oct 9;11(1):5120. PubMed PMID: 33037194; PubMed Central PMCID: PMCPMC7547708. DOI:https://doi.org/10.1038/s41467-020-18794-x.
- Nallanthighal S, Heiserman JP, Cheon DJ. the role of the extracellular matrix in cancer stemness. Front Cell Dev Biol. 2019;7:86. DOI:https://doi.org/10.3389/fcell.2019.00086. PubMed PMID: 31334229; PubMed Central PMCID: PMCPMC6624409.
- Heneberg P. Paracrine tumor signaling induces transdifferentiation of surrounding fibroblasts. Crit Rev Oncol Hematol. 2016Jan; 97: 303–311.https://doi.org/10.1016/j.critrevonc.2015.09.008 PubMed PMID: 26467073
- Webber J, Steadman R, Mason MD, et al. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010 Dec 1;70(23):9621–9630. PubMed PMID: 21098712. DOI:https://doi.org/10.1158/0008-5472.CAN-10-1722.
- Girigoswami K, Saini D, Girigoswami A. Extracellular matrix remodeling and development of cancer. Stem Cell Rev Rep. 2021Jun;17(3):739–747. PubMed PMID: 33128168. https://doi.org/10.1007/s12015-020-10070-1
- Mpekris F, Voutouri C, Baish JW, et al. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3728–3737. PubMed PMID: 32015113; PubMed Central PMCID: PMCPMC7035612. DOI:https://doi.org/10.1073/pnas.1919764117.
- Dvorak HF. Tumor stroma, tumor blood vessels, and antiangiogenesis therapy. Cancer J. 2015;21(4):237–243. PubMed PMID: 00130404-201507000-00002. DOI:https://doi.org/10.1097/ppo.0000000000000124
- Gouarderes S, Mingotaud AF, Vicendo P, et al. Vascular and extracellular matrix remodeling by physical approaches to improve drug delivery at the tumor site. Expert Opin Drug Deliv. 2020Dec;1712:1703–1726. https://doi.org/10.1080/17425247.2020.1814735 PubMed PMID: 32838565
- Truong LH, Pauklin S. Pancreatic cancer microenvironment and cellular composition: current understandings and therapeutic approaches. Cancers (Basel). 2021 Oct 8;13(19):5028. DOI:https://doi.org/10.3390/cancers13195028. PubMed PMID: 34638513; PubMed Central PMCID: PMCPMC8507722.
- Guo Z, Hu Y, Zhao M, et al. Prodrug-based versatile nanomedicine with simultaneous physical and physiological tumor penetration for enhanced cancer chemo-immunotherapy. Nano Lett. 2021 May 12;21(9):3721–3730. PubMed PMID: 33891423. DOI:https://doi.org/10.1021/acs.nanolett.0c04772.
- Luo K, Yin S, Zhang R, et al. Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy. Int J Pharm. 2020 Nov 15;589:119870. DOI:https://doi.org/10.1016/j.ijpharm.2020.119870. PubMed PMID: 32919005.
- Chen E, Han S, Song B, et al. Mechanism investigation of hyaluronidase-combined multistage nanoparticles for solid tumor penetration and antitumor effect. Int J Nanomedicine. 2020;15:6311–6324. PubMed PMID: 32922003; PubMed Central PMCID: PMCPMC7458542. DOI:https://doi.org/10.2147/IJN.S257164
- Zinger A, Koren L, Adir O, et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors. ACS Nano. 2019 Oct 22;13(10):11008–11021. PubMed PMID: 31503443; PubMed Central PMCID: PMCPMC6837877. DOI:https://doi.org/10.1021/acsnano.9b02395.
- Mateo C, Palomo JM, Fernandez-Lorente G, et al. Improvement of enzyme activity, stability and selectivity via immobilization techniques. Enzyme Microb Technol. 2007;40(6):1451–1463.
- Zhou H, Fan Z, Deng J, et al. Hyaluronidase embedded in nanocarrier peg shell for enhanced tumor penetration and highly efficient antitumor efficacy. Nano Lett. 2016 May 11;16(5):3268–3277. PubMed PMID: 27057591. DOI:https://doi.org/10.1021/acs.nanolett.6b00820.
- Cox TR. The matrix in cancer. Nat Rev Cancer. 2021Apr;21(4):217–238. PubMed PMID: 33589810. https://doi.org/10.1038/s41568-020-00329-7
- Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014 Jun 16;25(6):719–734. PubMed PMID: 24856586; PubMed Central PMCID: PMCPMC4180632. DOI:https://doi.org/10.1016/j.ccr.2014.04.005.
- Rucki AA, Foley K, Zhang P, et al. Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res. 2017 Jan 1;77(1):41–52. PubMed PMID: 27821486; PubMed Central PMCID: PMCPMC5245778. DOI:https://doi.org/10.1158/0008-5472.CAN-16-1383.
- Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014 Jun 16;25(6):735–747. PubMed PMID: 24856585; PubMed Central PMCID: PMCPMC4096698. DOI:https://doi.org/10.1016/j.ccr.2014.04.021.
- Apte MV, Wilson JS, Lugea A, et al. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology. 2013Jun;1446:1210–1219. https://doi.org/10.1053/j.gastro.2012.11.037 PubMed PMID: 23622130; PubMed Central PMCID: PMCPMC3729446
- Saha S, Xiong X, Chakraborty PK, et al. Gold nanoparticle reprograms pancreatic tumor microenvironment and inhibits tumor growth. ACS Nano. 2016 Dec 27;10(12):10636–10651. PubMed PMID: 27758098; PubMed Central PMCID: PMCPMC6939886. DOI:https://doi.org/10.1021/acsnano.6b02231.
- Ji T, Li S, Zhang Y, et al. An MMP-2 responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer. ACS Appl Mater Interfaces. 2016 Feb 10;8(5):3438–3445. PubMed PMID: 26759926. DOI:https://doi.org/10.1021/acsami.5b11619.
- Ji T, Lang J, Wang J, et al. Designing liposomes to suppress extracellular matrix expression to enhance drug penetration and pancreatic tumor therapy. ACS Nano. 2017 Sep 26;11(9):8668–8678. PubMed PMID: 28806504. DOI:https://doi.org/10.1021/acsnano.7b01026.
- Zhao J, Xiao Z, Li T, et al. Stromal modulation reverses primary resistance to immune checkpoint blockade in pancreatic cancer. ACS Nano. 2018 Oct 23;12(10):9881–9893. PubMed PMID: 30231203; PubMed Central PMCID: PMCPMC6245606. DOI:https://doi.org/10.1021/acsnano.8b02481.
- Huang Y, Jin C, Yu J, et al. A novel multifunctional 2-nitroimidazole-based bioreductive linker and its application in hypoxia-activated prodrugs. Bioorg Chem. 2020 Aug;101:103975. PubMed PMID: 32474180 https://doi.org/10.1016/j.bioorg.2020.103975
- Meng F, Evans JW, Bhupathi D, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther. 2012Mar;113:740–751. https://doi.org/10.1158/1535-7163.MCT-11-0634 PubMed PMID: 22147748
- Zeng Y, Ma J, Zhan Y, et al. Hypoxia-activated prodrugs and redox-responsive nanocarriers. Int J Nanomedicine. 2018;13:6551–6574. PubMed PMID: 30425475; PubMed Central PMCID: PMCPMC6202002. DOI:https://doi.org/10.2147/IJN.S173431
- Bertozzi D, Marinello J, Manzo SG, et al. The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1alpha activity by changing miR expression patterns in human cancer cells. Mol Cancer Ther. 2014Jan;131:239–248. https://doi.org/10.1158/1535-7163.MCT-13-0729 PubMed PMID: 24252850
- Jin C, Zhang Q, Lu W. Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38. Eur J Med Chem. 2017 May 26;132:135–141. DOI:https://doi.org/10.1016/j.ejmech.2017.03.040. PubMed PMID: 28350997.
- Zhang K, Zhang Y, Meng X, et al. Light-triggered theranostic liposomes for tumor diagnosis and combined photodynamic and hypoxia-activated prodrug therapy. Biomaterials. 2018 Dec;185:301–309. PubMed PMID: 30265899 https://doi.org/10.1016/j.biomaterials.2018.09.033
- Shah VM, Nguyen DX, Al Fatease A, et al. Liposomal formulation of hypoxia activated prodrug for the treatment of ovarian cancer. J Control Release. 2018 Dec 10;291:169–183. DOI:https://doi.org/10.1016/j.jconrel.2018.10.021. PubMed PMID: 30339904.
- Phillips RM. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother Pharmacol. 2016Mar;77(3):441–457. PubMed PMID: 26811177; PubMed Central PMCID: PMCPMC4767869. https://doi.org/10.1007/s00280-015-2920-7
- Liu Y, Jiang Y, Zhang M, et al. Modulating hypoxia via nanomaterials chemistry for efficient treatment of solid tumors. Acc Chem Res. 2018 Oct 16;51(10):2502–2511. PubMed PMID: 30234960. DOI:https://doi.org/10.1021/acs.accounts.8b00214.
- Castaldo SA, Ajime T, Serrao G, et al. Annexin A2 regulates akt upon h(2)o(2)-dependent signaling activation in cancer cells. Cancers (Basel). 2019 Apr 7;11(4):492. PubMed PMID: 30959964; PubMed Central PMCID: PMCPMC6520733. DOI:https://doi.org/10.3390/cancers11040492.
- Kim J, Cho HR, Jeon H, et al. Continuous O2-evolving mnfe2o4 nanoparticle-anchored mesoporous silica nanoparticles for efficient photodynamic therapy in hypoxic cancer. J Am Chem Soc. 2017 Aug 16;139(32):10992–10995. PubMed PMID: 28737393. DOI:https://doi.org/10.1021/jacs.7b05559.
- Shi C, Li M, Zhang Z, et al. Catalase-based liposomal for reversing immunosuppressive tumor microenvironment and enhanced cancer chemo-photodynamic therapy. Biomaterials. 2020;233. DOI:https://doi.org/10.1016/j.biomaterials.2020.119755.
- Chen M, Song J, Zhu J, et al. A dual-nanozyme-catalyzed cascade reactor for enhanced photodynamic oncotherapy against tumor hypoxia. Adv Healthc Mater. 2021Nov;10(21):e2101049. https://doi.org/10.1002/adhm.202101049 PubMed PMID: 34494723
- Liu C, Wang D, Zhang S, et al. Biodegradable biomimic copper/manganese silicate nanospheres for chemodynamic/photodynamic synergistic therapy with simultaneous glutathione depletion and hypoxia relief. ACS Nano. 2019 Apr 23;13(4):4267–4277. PubMed PMID: 30901515. DOI:https://doi.org/10.1021/acsnano.8b09387.
- Jiang W, Zhang Z, Wang Q, et al. Tumor reoxygenation and blood perfusion enhanced photodynamic therapy using ultrathin graphdiyne oxide nanosheets. Nano Lett. 2019 Jun 12;19(6):4060–4067. PubMed PMID: 31136712. DOI:https://doi.org/10.1021/acs.nanolett.9b01458.
- McEwan C, Owen J, Stride E, et al. Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours. J Control Release. 2015 Apr 10;203:51–56. DOI:https://doi.org/10.1016/j.jconrel.2015.02.004. PubMed PMID: 25660073.
- McEwan C, Kamila S, Owen J, et al. Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle. Biomaterials. 2016 Feb;80:20–32. PubMed PMID: 26702983 https://doi.org/10.1016/j.biomaterials.2015.11.033
- Cook CA, Hahn KC, Morrissette-mcalmon JB, et al. Oxygen delivery from hyperbarically loaded microtanks extends cell viability in anoxic environments. Biomaterials. 2015 Jun;52:376–384. PubMed PMID: 25818444; PubMed Central PMCID: PMCPMC4955786 https://doi.org/10.1016/j.biomaterials.2015.02.036
- Wang W, Cheng Y, Yu P, et al. Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy. Nat Commun. 2019 Apr 5;10(1):1580. PubMed PMID: 30952842; PubMed Central PMCID: PMCPMC6450981. DOI:https://doi.org/10.1038/s41467-019-09389-2.
- Song X, Feng L, Liang C, et al. Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies. Nano Lett. 2016 Oct 12;16(10):6145–6153. PubMed PMID: 27622835. DOI:https://doi.org/10.1021/acs.nanolett.6b02365.
- Cao H, Wang L, Yang Y, et al. An assembled nanocomplex for improving both therapeutic efficiency and treatment depth in photodynamic therapy. Angew Chem Int Ed Engl. 2018 Jun 25;57(26):7759–7763. PubMed PMID: 29704295. DOI:https://doi.org/10.1002/anie.201802497.
- Jiang L, Bai H, Liu L, et al. Luminescent, oxygen-supplying, hemoglobin-linked conjugated polymer nanoparticles for photodynamic therapy. Angew Chem Int Ed Engl. 2019 Jul 29;58(31):10660–10665. PubMed PMID: 31173456. DOI:https://doi.org/10.1002/anie.201905884.
- Chen J, Luo H, Liu Y, et al. Oxygen-self-produced nanoplatform for relieving hypoxia and breaking resistance to sonodynamic treatment of pancreatic cancer. ACS Nano. 2017 Dec 26;11(12):12849–12862. PubMed PMID: 29236476. DOI:https://doi.org/10.1021/acsnano.7b08225.
- Liu Q, Li Y, Niu Z, et al. Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages. J Exp Clin Cancer Res. 2016 Feb 16;35:33. DOI:https://doi.org/10.1186/s13046-016-0304-4. PubMed PMID: 26879926; PubMed Central PMCID: PMCPMC4754966.
- Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007 Oct 1;67(19):9518–9527. PubMed PMID: 17909062. DOI:https://doi.org/10.1158/0008-5472.CAN-07-0175.
- D’Costa Z, Jones K, Azad A, et al. Gemcitabine-induced timp1 attenuates therapy response and promotes tumor growth and liver metastasis in pancreatic cancer. Cancer Res. 2017 Nov 1;77(21):5952–5962. PubMed PMID: 28765154. DOI:https://doi.org/10.1158/0008-5472.CAN-16-2833.
- Nishino M, Ramaiya NH, Hatabu H, et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017Nov;1411:655–668. https://doi.org/10.1038/nrclinonc.2017.88 PubMed PMID: 28653677; PubMed Central PMCID: PMCPMC5650537
- Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019 Feb 1;30(2):219–235. PubMed PMID: 30608567. DOI:https://doi.org/10.1093/annonc/mdy551.
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264. DOI:https://doi.org/10.1038/nrc3239. PubMed PMID: 22437870; PubMed Central PMCID: PMCPMC4856023.
- Li R, Ma C, Cai H, et al. The CAR T-cell mechanoimmunology at a glance. Adv Sci (Weinh). 2020Dec;724:2002628. https://doi.org/10.1002/advs.202002628 PubMed PMID: 33344135; PubMed Central PMCID: PMCPMC7740088
- Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020 Oct 12;38(4):473–488. DOI:https://doi.org/10.1016/j.ccell.2020.07.005. PubMed PMID: 32735779.
- Tran T, Blanc C, Granier C, et al. Therapeutic cancer vaccine: building the future from lessons of the past. Semin Immunopathol. 2019Jan;411:69–85. https://doi.org/10.1007/s00281-018-0691-z PubMed PMID: 29978248
- Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011 May 15;167(2):e211–9. PubMed PMID: 19765725. DOI:https://doi.org/10.1016/j.jss.2009.05.026.
- Penny HL, Sieow JL, Adriani G, et al. Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. Oncoimmunology. 2016Aug;58:e1191731. https://doi.org/10.1080/2162402X.2016.1191731 PubMed PMID: 27622062; PubMed Central PMCID: PMCPMC5007961
- Prima V, Kaliberova LN, Kaliberov S, et al. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1117–1122. PubMed PMID: 28096371; PubMed Central PMCID: PMCPMC5293015. DOI:https://doi.org/10.1073/pnas.1612920114.
- Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010Jun;31(6):220–227. PubMed PMID: 20538542; PubMed Central PMCID: PMCPMC2891151. https://doi.org/10.1016/j.it.2010.04.002
- Hou P, Kapoor A, Zhang Q, et al. Tumor microenvironment remodeling enables bypass of oncogenic kras dependency in pancreatic cancer. Cancer Discov. 2020Jul;10(7):1058–1077. https://doi.org/10.1158/2159-8290.CD-19-0597 PubMed PMID: 32341020; PubMed Central PMCID: PMCPMC7334087
- Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009 Jun 8;206(6):1327–1337. PubMed PMID: 19451266; PubMed Central PMCID: PMCPMC2715058. DOI:https://doi.org/10.1084/jem.20082173.
- Ovais M, Guo M, Chen C. Tailoring nanomaterials for targeting tumor-associated macrophages. Adv Mater. 2019May;31(19):e1808303. PubMed PMID: 30883982. https://doi.org/10.1002/adma.201808303
- Singh Y, Pawar VK, Meher JG, et al. Targeting tumor associated macrophages (TAMs) via nanocarriers. J Control Release. 2017 May 28;254:92–106. DOI:https://doi.org/10.1016/j.jconrel.2017.03.395. PubMed PMID: 28377038.
- Poh AR, Ernst M. Tumor-associated macrophages in pancreatic ductal adenocarcinoma: therapeutic opportunities and clinical challenges. Cancers (Basel). 2021 Jun 8;13(12):2860. DOI:https://doi.org/10.3390/cancers13122860. PubMed PMID: 34201127; PubMed Central PMCID: PMCPMC8226457.
- Zhang X, Detering L, Sultan D, et al. CC chemokine receptor 2-targeting copper nanoparticles for positron emission tomography-guided delivery of gemcitabine for pancreatic ductal adenocarcinoma. ACS Nano. 2021 Jan 26;15(1):1186–1198. PubMed PMID: 33406361; PubMed Central PMCID: PMCPMC7846978. DOI:https://doi.org/10.1021/acsnano.0c08185.
- Chen Y, Huang Y, Zhou S, et al. Tailored chemodynamic nanomedicine improves pancreatic cancer treatment via controllable damaging neoplastic cells and reprogramming tumor microenvironment. Nano Lett. 2020 Sep 9;20(9):6780–6790. PubMed PMID: 32809834. DOI:https://doi.org/10.1021/acs.nanolett.0c02622.
- Gabrilovich DI, Velders MP, Sotomayor EM, et al. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001 May 1;166(9):5398–5406. PubMed PMID: 11313376. DOI:https://doi.org/10.4049/jimmunol.166.9.5398.
- Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018Feb;19(2):108–119. PubMed PMID: 29348500; PubMed Central PMCID: PMCPMC5854158. https://doi.org/10.1038/s41590-017-0022-x
- Otsuji M, Kimura Y, Aoe T, et al. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A. 1996;93(23):13119–13124. PubMed PMID: 8917554; eng. DOI:https://doi.org/10.1073/pnas.93.23.13119
- Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012Sep;619:1373–1385. https://doi.org/10.1007/s00262-011-1178-0 PubMed PMID: 22215137; PubMed Central PMCID: PMCPMC3697836
- Ku AW, Muhitch JB, Powers CA, et al. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife. 2016 Dec 8;5:https://doi.org/10.7554/eLife.17375 PubMed PMID: 27929373; PubMed Central PMCID: PMCPMC5199197
- Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006 Jan 15;66(2):1123–1131. PubMed PMID: 16424049. DOI:https://doi.org/10.1158/0008-5472.CAN-05-1299.
- Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008Apr; 222: 180–191.https://doi.org/10.1111/j.1600-065X.2008.00608.x PubMed PMID: 18364002; PubMed Central PMCID: PMCPMC3546504
- Yoyen-Ermis D, Ozturk-Atar K, Kursunel MA, et al. Tumor-induced myeloid cells are reduced by gemcitabine-loaded pamam dendrimers decorated with anti-flt1 antibody. Mol Pharm. 2018;15(4):1526–1533.
- Lu Z, Long Y, Wang Y, et al. Phenylboronic acid modified nanoparticles simultaneously target pancreatic cancer and its metastasis and alleviate immunosuppression. Eur J Pharm Biopharm. 2021 Aug;165:164–173. PubMed PMID: 34020022 https://doi.org/10.1016/j.ejpb.2021.05.014
- Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016Jul; 58: 59–70.https://doi.org/10.1016/j.oraloncology.2016.05.002 PubMed PMID: 27215705; PubMed Central PMCID: PMCPMC4912416
- Yu M, Duan X, Cai Y, et al. Multifunctional nanoregulator reshapes immune microenvironment and enhances immune memory for tumor immunotherapy. Adv Sci (Weinh). 2019 Aug 21;6(16):1900037. PubMed PMID: 31453054; PubMed Central PMCID: PMCPMC6702652. DOI: https://doi.org/10.1002/advs.201900037.
- Yang L, Sun J, Liu Q, et al. Synergetic functional nanocomposites enhance immunotherapy in solid tumors by remodeling the immunoenvironment. Adv Sci (Weinh). 2019 Apr 17;6(8):1802012. PubMed PMID: 31016114; PubMed Central PMCID: PMCPMC6469336. DOI:https://doi.org/10.1002/advs.201802012.
- Lorkowski ME, Atukorale PU, Bielecki PA, et al. Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. J Control Release. 2021 Feb 10;330:1095–1105. DOI:https://doi.org/10.1016/j.jconrel.2020.11.014. PubMed PMID: 33188827; PubMed Central PMCID: PMCPMC7906920.
- Chen P, Liu X, Sun Y, et al. Dendritic cell targeted vaccines: recent progresses and challenges. Hum Vaccin Immunother. 2016 Mar 3;12(3):612–622. PubMed PMID: 26513200; PubMed Central PMCID: PMCPMC4964742. DOI:https://doi.org/10.1080/21645515.2015.1105415.
- Behzadi S, Serpooshan V, Tao W, et al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev. 2017 Jul 17;46(14):4218–4244. PubMed PMID: 28585944; PubMed Central PMCID: PMCPMC5593313. DOI:https://doi.org/10.1039/c6cs00636a.
- Irvine DJ, Hanson MC, Rakhra K, et al. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev. 2015 Oct 14;115(19):11109–11146. PubMed PMID: 26154342; PubMed Central PMCID: PMCPMC4688911. DOI:https://doi.org/10.1021/acs.chemrev.5b00109.
- Zhang Y, Lin S, Wang XY, et al. Nanovaccines for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019Sep;115:e1559. https://doi.org/10.1002/wnan.1559 PubMed PMID: 31172659; PubMed Central PMCID: PMCPMC7040494
- Musetti S, Huang L. Nanoparticle-mediated remodeling of the tumor microenvironment to Enhance Immunotherapy. ACS Nano. 2018 Dec 26;12(12):11740–11755. DOI:https://doi.org/10.1021/acsnano.8b05893. PubMed PMID: 30508378.
- Zhang L, Huang Y, Lindstrom AR, et al. Peptide-based materials for cancer immunotherapy. Theranostics. 2019;9(25):7807–7825. PubMed PMID: 31695802; PubMed Central PMCID: PMCPMC6831480. DOI:https://doi.org/10.7150/thno.37194
- Neek M, Kim TI, Wang SW. Protein-based nanoparticles in cancer vaccine development. Nanomedicine. 2019Jan;15(1):164–174. PubMed PMID: 30291897; PubMed Central PMCID: PMCPMC6289732. https://doi.org/10.1016/j.nano.2018.09.004
- Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005Apr;5(4):296–306. PubMed PMID: 15803149. https://doi.org/10.1038/nri1592
- Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019 Nov 27;10(1):5408. DOI:https://doi.org/10.1038/s41467-019-13368-y. PubMed PMID: 31776331; PubMed Central PMCID: PMCPMC6881351.
- Saxena M, Bhardwaj N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer. 2018Feb;4(2):119–137. PubMed PMID: 29458962; PubMed Central PMCID: PMCPMC5823288. https://doi.org/10.1016/j.trecan.2017.12.007
- Jahanafrooz Z, Baradaran B, Mosafer J, et al. Comparison of DNA and mRNA vaccines against cancer. Drug Discov Today. 2020Mar;253:552–560. https://doi.org/10.1016/j.drudis.2019.12.003 PubMed PMID: 31843577; PubMed Central PMCID: PMCPMC7080609
- Lopes A, Vandermeulen G, Preat V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res. 2019 Apr 5;38(1):146. DOI:https://doi.org/10.1186/s13046-019-1154-7. PubMed PMID: 30953535; PubMed Central PMCID: PMCPMC6449928.
- Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018Apr;174:261–279. https://doi.org/10.1038/nrd.2017.243 PubMed PMID: 29326426; PubMed Central PMCID: PMCPMC5906799
- Chiappinelli KB, Zahnow CA, Ahuja N, et al. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016 Apr 1;76(7):1683–1689. PubMed PMID: 26988985; PubMed Central PMCID: PMCPMC4873370. DOI:https://doi.org/10.1158/0008-5472.CAN-15-2125.
- Garnett-Benson C, Hodge JW, Gameiro SR. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol. 2015Jan;25(1):46–53. PubMed PMID: 25481266; PubMed Central PMCID: PMCPMC4258617. https://doi.org/10.1016/j.semradonc.2014.07.002
- Tang R, Xu J, Zhang B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020 Aug 10;13(1):110. PubMed PMID: 32778143; PubMed Central PMCID: PMCPMC7418434. DOI:https://doi.org/10.1186/s13045-020-00946-7.
- Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020Dec;14(12):2994–3006. PubMed PMID: 33179413; PubMed Central PMCID: PMCPMC7718954. https://doi.org/10.1002/1878-0261.12851
- Zhou J, Wang G, Chen Y, et al. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019Aug;238:4854–4865. https://doi.org/10.1111/jcmm.14356 PubMed PMID: 31210425; PubMed Central PMCID: PMCPMC6653385
- Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. PubMed PMID: 23157435. DOI:https://doi.org/10.1146/annurev-immunol-032712-100008
- Lu J, Liu X, Liao YP, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017 Nov 27;8(1):1811. PubMed PMID: 29180759; PubMed Central PMCID: PMCPMC5703845. DOI:https://doi.org/10.1038/s41467-017-01651-9.
- Liu X, Jiang J, Chang CH, et al. Development of facile and versatile platinum drug delivering silicasome nanocarriers for efficient pancreatic cancer chemo-immunotherapy. Small. 2021Apr;1714:e2005993. https://doi.org/10.1002/smll.202005993 PubMed PMID: 33682329; PubMed Central PMCID: PMCPMC8035264
- Liu X, Jiang J, Liao YP, et al. Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-1. Adv Sci (Weinh). 2021Mar;86:2002147. https://doi.org/10.1002/advs.202002147 PubMed PMID: 33747719; PubMed Central PMCID: PMCPMC7967046
- Huang L, Zhao S, Fang F, et al. Advances and perspectives in carrier-free nanodrugs for cancer chemo-monotherapy and combination therapy. Biomaterials. 2021 Jan;268:120557. PubMed PMID: 33260095 https://doi.org/10.1016/j.biomaterials.2020.120557
- Li L, Yang Z, Fan W, et al. In situ polymerized hollow mesoporous organosilica biocatalysis nanoreactor for enhancing ros-mediated anticancer therapy. Adv Funct Mater. 2020 Jan 23;30(4). DOI:https://doi.org/10.1002/adfm.201907716. PubMed PMID: 33041745; PubMed Central PMCID: PMCPMC7546450.
- Hussein EA, Zagho MM, Nasrallah GK, et al. Recent advances in functional nanostructures as cancer photothermal therapy. Int J Nanomedicine. 2018;13:2897–2906. PubMed PMID: 29844672; PubMed Central PMCID: PMCPMC5961635. DOI:https://doi.org/10.2147/IJN.S161031
- Hu Y, Lv T, Ma Y, et al. Nanoscale coordination polymers for synergistic no and chemodynamic therapy of liver cancer. Nano Lett. 2019 Apr 10;19(4):2731–2738. PubMed PMID: 30919635. DOI:https://doi.org/10.1021/acs.nanolett.9b01093.
- Ji M, Xu M, Zhang W, et al. Structurally well-defined au@cu2- x s core-shell nanocrystals for improved cancer treatment based on enhanced photothermal efficiency. Adv Mater. 2016Apr;2816:3094–3101. https://doi.org/10.1002/adma.201503201 PubMed PMID: 26913692
- Tang X, Tan L, Shi K, et al. Gold nanorods together with HSP inhibitor-VER-155008 micelles for colon cancer mild-temperature photothermal therapy. Acta Pharm Sin B. 2018Jul;84:587–601. https://doi.org/10.1016/j.apsb.2018.05.011 PubMed PMID: 30109183; PubMed Central PMCID: PMCPMC6089863
- Huang X, Yin Y, Wu M, et al. LyP-1 peptide-functionalized gold nanoprisms for SERRS imaging and tumor growth suppressing by PTT induced-hyperthermia. Chin Chem Lett. 2019;30(6):1335–1340.
- Shi X, Li Q, Zhang C, et al. Semiconducting polymer nano-radiopharmaceutical for combined radio-photothermal therapy of pancreatic tumor. J Nanobiotechnology. 2021 Oct 24;19(1):337. PubMed PMID: 34689758; PubMed Central PMCID: PMCPMC8543882. DOI:https://doi.org/10.1186/s12951-021-01083-0.
- Wang M, Li Y, Wang M, et al. Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer. Acta Biomater. 2021 Oct 30. DOI:https://doi.org/10.1016/j.actbio.2021.10.048. PubMed PMID: 34757232.
- Lin R, Yu W, Chen X, et al. Self-propelled micro/nanomotors for tumor targeting delivery and therapy. Adv Healthc Mater. 2021Jan;10(1):e2001212. https://doi.org/10.1002/adhm.202001212 PubMed PMID: 32975892
- Wan M, Chen H, Wang Q, et al. Bio-inspired nitric-oxide-driven nanomotor. Nat Commun. 2019 Feb 27;10(1):966. PubMed PMID: 30814497; PubMed Central PMCID: PMCPMC6393443. DOI:https://doi.org/10.1038/s41467-019-08670-8.
- Yu W, Lin R, He X, et al. Self-propelled nanomotor reconstructs tumor microenvironment through synergistic hypoxia alleviation and glycolysis inhibition for promoted anti-metastasis. Acta Pharm Sin B. 2021Sep;119:2924–2936. https://doi.org/10.1016/j.apsb.2021.04.006 PubMed PMID: 34589405; PubMed Central PMCID: PMCPMC8463459
- Ji Y, Lin X, Wu Z, et al. Macroscale chemotaxis from a swarm of bacteria-mimicking nanoswimmers. Angew Chem Int Ed Engl. 2019 Aug 26;58(35):12200–12205. PubMed PMID: 31282598. DOI:https://doi.org/10.1002/anie.201907733.
- Hortelao AC, Carrascosa R, Murillo-Cremaes N, et al. Targeting 3D bladder cancer spheroids with urease-powered nanomotors. ACS Nano. 2019 Jan 22;13(1):429–439. PubMed PMID: 30588798. DOI:https://doi.org/10.1021/acsnano.8b06610.
- Llopis-Lorente A, Garcia-Fernandez A, Murillo-Cremaes N, et al. Enzyme-powered gated mesoporous silica nanomotors for on-command intracellular payload delivery. ACS Nano. 2019 Oct 22;13(10):12171–12183. PubMed PMID: 31580642. DOI:https://doi.org/10.1021/acsnano.9b06706.
- Ye Y, Tong F, Wang S, et al. Apoptotic tumor dna activated nanomotor chemotaxis. Nano Lett. 2021 Oct 13;21(19):8086–8094. PubMed PMID: 34559543. DOI:https://doi.org/10.1021/acs.nanolett.1c02441.
- Peng H, Li XF, Zhang H, et al. A microRNA-initiated DNAzyme motor operating in living cells. Nat Commun. 2017 Mar 6;8:14378. DOI:https://doi.org/10.1038/ncomms14378. PubMed PMID: 28262725; PubMed Central PMCID: PMCPMC5343503.
- Li T, Chen T, Chen H, et al. Engineered platelet-based micro/nanomotors for cancer therapy. Small. 2021 Nov;5:e2104912. PubMed PMID: 34741421 https://doi.org/10.1002/smll.202104912
- Shen Y, Zhang W, Li G, et al. Adaptive control of nanomotor swarms for magnetic-field-programmed cancer cell destruction. ACS Nano. 2021 Nov 22;15:20020–20031. DOI:https://doi.org/10.1021/acsnano.1c07615. PubMed PMID: 34807565.
- Hansen-Bruhn M, de Avila BE, Beltran-Gastelum M, et al. Active intracellular delivery of a cas9/sgrna complex using ultrasound-propelled nanomotors. Angew Chem Int Ed Engl. 2018 Mar 1;57(10):2657–2661. PubMed PMID: 29325201. DOI:https://doi.org/10.1002/anie.201713082.
- Akolpoglu MB, Dogan NO, Bozuyuk U, et al. High-yield production of biohybrid microalgae for on-demand cargo delivery. Adv Sci (Weinh). 2020Aug;716:2001256. https://doi.org/10.1002/advs.202001256 PubMed PMID: 32832367; PubMed Central PMCID: PMCPMC7435244
- Yasa O, Erkoc P, Alapan Y, et al. Microalga-powered microswimmers toward active cargo delivery. Adv Mater. 2018Nov;30(45):e1804130. https://doi.org/10.1002/adma.201804130 PubMed PMID: 30252963
- Senturk OI, Schauer O, Chen F, et al. Red/far-red light switchable cargo attachment and release in bacteria-driven microswimmers. Adv Healthc Mater. 2020Jan;91:e1900956. https://doi.org/10.1002/adhm.201900956 PubMed PMID: 31596552
- Xu H, Medina-Sanchez M, Magdanz V, et al. Sperm-hybrid micromotor for targeted drug delivery. ACS Nano. 2018 Jan 23;12(1):327–337. PubMed PMID: 29202221. DOI:https://doi.org/10.1021/acsnano.7b06398.
- Ding L, Wu Y, Wu M, et al. Engineered red blood cell biomimetic nanovesicle with oxygen self-supply for near-infrared-ii fluorescence-guided synergetic chemo-photodynamic therapy against hypoxic tumors. ACS Appl Mater Interfaces. 2021 Oct 27. DOI:https://doi.org/10.1021/acsami.1c19096. PubMed PMID: 34705421.
- Yuan P, Dou G, Liu T, et al. On-demand manipulation of tumorigenic microenvironments by nano-modulator for synergistic tumor therapy. Biomaterials. 2021 Aug;275:120956. PubMed PMID: 34146890 https://doi.org/10.1016/j.biomaterials.2021.120956
- Zheng T, Wang W, Ashley J, et al. Self-assembly protein superstructures as a powerful chemodynamic therapy nanoagent for glioblastoma treatment. Nanomicro Lett. 2020 Jul 15;12(1):151. PubMed PMID: 34138164; PubMed Central PMCID: PMCPMC7770858. DOI:https://doi.org/10.1007/s40820-020-00490-6.